Dec. 20, 2013News & Opinions
The Supervisory Board of Bayer AG appointed Kemal Malik (51) to the Board of Management of Bayer AG effective February 1, 2014. Malik has been a member of the Bayer HealthCare Executive Committee, Head of Global Development and Chief ...
Oct. 07, 2013News & Opinions
German healthcare company Merck expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin.
Jul. 11, 2013News & Opinions
Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss company as it struggles to diversify outside its core cancer drug portfolio.
Jun. 19, 2013News & Opinions
Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
Jun. 11, 2013News & Opinions
A former Bristol-Myers Squibb finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.
Jun. 07, 2013News & Opinions
In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43 billion-a-year diabetes market.
Jun. 06, 2013News & Opinions
Inspired by its success in high-tech electronics and software, Israel is hoping to pull off the same trick in life sciences.
May. 03, 2013News & Opinions
Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
Apr. 08, 2013News & Opinions
U.S. drugmaker Bristol-Myers Squibb said on Sunday it has named Francis Cuss to become its next chief scientific officer after Elliott Sigal retires as head of research and development on June 30.
Apr. 02, 2013News & Opinions
India's top court dismissed Swiss drugmaker Novartis's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
The latest information directly via newsletter.